Literature DB >> 24146121

Targeting interleukin-1 in heart disease.

Benjamin W Van Tassell1, Stefano Toldo, Eleonora Mezzaroma, Antonio Abbate.   

Abstract

Entities:  

Keywords:  heart diseases; inflammation; interleukins

Mesh：

Substances：

Year:  2013        PMID： 24146121      PMCID： PMC3938092          DOI： 10.1161/CIRCULATIONAHA.113.003199

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  144 in total

Review 1.  Canakinumab: in patients with cryopyrin-associated periodic syndromes.

Authors:  Monique P Curran
Journal:  BioDrugs       Date:  2012-02-01       Impact factor: 5.807

Review 2.  The interface of atherosclerosis and thrombosis: basic mechanisms.

Authors:  P Libby
Journal:  Vasc Med       Date:  1998       Impact factor: 3.239

3.  Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity.

Authors:  Jinzhou Zhu; Jing Zhang; Di Xiang; Zhonghui Zhang; Lin Zhang; Mingyuan Wu; Shunying Zhu; Ruiyan Zhang; Wei Han
Journal:  Eur J Pharmacol       Date:  2010-06-30       Impact factor: 4.432

4.  Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group.

Authors:  S M Opal; C J Fisher; J F Dhainaut; J L Vincent; R Brase; S F Lowry; J C Sadoff; G J Slotman; H Levy; R A Balk; M P Shelly; J P Pribble; J F LaBrecque; J Lookabaugh; H Donovan; H Dubin; R Baughman; J Norman; E DeMaria; K Matzel; E Abraham; M Seneff
Journal:  Crit Care Med       Date:  1997-07       Impact factor: 7.598

5.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.

Authors:  B J Pomerantz; L L Reznikov; A H Harken; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

6.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.

Authors:  Ahmet Gül; Ilknur Tugal-Tutkun; Charles A Dinarello; Leonid Reznikov; Bahar Artim Esen; Amer Mirza; Patrick Scannon; Alan Solinger
Journal:  Ann Rheum Dis       Date:  2011-11-14       Impact factor: 19.103

7.  Septic cardiomyopathy - A not yet discovered cardiomyopathy?

Authors:  Ursula Muller-Werdan; Michael Buerke; Henning Ebelt; Konstantin M Heinroth; Anja Herklotz; Harald Loppnow; Martin Ruß; Frithjof Schlegel; Axel Schlitt; Hendrik B Schmidt; Gerold Söffker; Karl Werdan
Journal:  Exp Clin Cardiol       Date:  2006

Review 8.  Gene polymorphisms of interleukins 1 and 10 in infectious and autoimmune diseases.

Authors:  M Hurme; N Lahdenpohja; S Santtila
Journal:  Ann Med       Date:  1998-10       Impact factor: 4.709

9.  The role of nitric oxide in cardiac depression induced by interleukin-1 beta and tumour necrosis factor-alpha.

Authors:  R Schulz; D L Panas; R Catena; S Moncada; P M Olley; G D Lopaschuk
Journal:  Br J Pharmacol       Date:  1995-01       Impact factor: 8.739

10.  Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells.

Authors:  M P Bevilacqua; J S Pober; G R Majeau; R S Cotran; M A Gimbrone
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307
View more
  106 in total

1.  Evaluation of Innate Immunity Biomarkers on Admission and at Discharge From an Acute Heart Failure Episode.

Authors:  Nuno Silva; Emília Patrício; Paulo Bettencourt; João Tiago Guimarães
Journal:  J Clin Lab Anal       Date:  2016-07-08       Impact factor: 2.352

2.  Preventing Heart Failure in Inflammatory and Immune Disorders.

Authors:  Maya Serhal; Chris T Longenecker
Journal:  Curr Cardiovasc Risk Rep       Date:  2014-06

Review 3.  Interleukin-1 blockade for the treatment of pericarditis.

Authors:  Leo F Buckley; Michele M Viscusi; Benjamin W Van Tassell; Antonio Abbate
Journal:  Eur Heart J Cardiovasc Pharmacother       Date:  2018-01-01

Review 4.  Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.

Authors:  Razi Khan; Eric Rheaume; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2018-09-15       Impact factor: 5.113

5.  Interleukin-1 blockade in heart failure with preserved ejection fraction: rationale and design of the Diastolic Heart Failure Anakinra Response Trial 2 (D-HART2).

Authors:  Benjamin W Van Tassell; Leo F Buckley; Salvatore Carbone; Cory R Trankle; Justin M Canada; Dave L Dixon; Nayef Abouzaki; Claudia Oddi-Erdle; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2017-05-05       Impact factor: 2.882

6.  Rationale and design of the Virginia Commonwealth University-Anakinra Remodeling Trial-3 (VCU-ART3): A randomized, placebo-controlled, double-blinded, multicenter study.

Authors:  Benjamin W Van Tassell; Michael J Lipinski; Darryn Appleton; Charlotte S Roberts; Michael C Kontos; Nayef Abouzaki; Ryan Melchior; George Mueller; James Garnett; Justin Canada; Salvatore Carbone; Leo F Buckley; George Wohlford; Dinesh Kadariya; Cory R Trankle; Claudia Oddi Erdle; Robin Sculthorpe; Laura Puckett; Christine DeWilde; Keyur Shah; Dominick J Angiolillo; George Vetrovec; Giuseppe Biondi-Zoccai; Ross Arena; Antonio Abbate
Journal:  Clin Cardiol       Date:  2018-08-17       Impact factor: 2.882

Review 7.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

8.  Cell biological mechanisms in regulation of the post-infarction inflammatory response.

Authors:  Nikolaos G Frangogiannis
Journal:  Curr Opin Physiol       Date:  2017-12-13

9.  Impact of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio on 5-Year Clinical Outcomes of Patients with Stable Coronary Artery Disease Undergoing Elective Percutaneous Coronary Intervention.

Authors:  Edoardo Bressi; Fabio Mangiacapra; Elisabetta Ricottini; Ilaria Cavallari; Iginio Colaiori; Giuseppe Di Gioia; Antonio Creta; Marialessia Capuano; Michele Mattia Viscusi; Germano Di Sciascio
Journal:  J Cardiovasc Transl Res       Date:  2018-10-01       Impact factor: 4.132

10.  Pharmacologic Inhibition of the NLRP3 Inflammasome Preserves Cardiac Function After Ischemic and Nonischemic Injury in the Mouse.

Authors:  Carlo Marchetti; Stefano Toldo; Jeremy Chojnacki; Eleonora Mezzaroma; Kai Liu; Fadi N Salloum; Andrea Nordio; Salvatore Carbone; Adolfo Gabriele Mauro; Anindita Das; Ankit A Zalavadia; Matthew S Halquist; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2015-07       Impact factor: 3.105
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.